Janku Filip

Chief Medical Officer

Janku Filip has filed 5 SEC Form 4 filings (11 transaction rows) across 1 company, with disclosures dating back to 2026. 5 of those filings fall inside the rolling window. Most recent filing: Jul 1, 2026.

On the most recent filing, Janku Filip is listed as Chief Medical Officer at Monte Rosa Therapeutics, Inc. Inside the rolling window, Janku Filip reported no open-market purchases and 6 open-market sales totaling $1.4M in GLUE. The largest disclosed transaction in the window is a sale of 30,000 GLUE shares on Jun 24, 2026, worth $643K.

Companies traded

Other insiders at GLUE

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$1.4M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
GLUESale$132KJul 1SEC ↗
GLUESale$138KJun 30SEC ↗
GLUESale$240KJun 25SEC ↗
GLUESale$643KJun 25SEC ↗
GLUESale$179KFeb 24SEC ↗
GLUESale$48KJan 5SEC ↗
Showing 1–6 of 6
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Janku Filip made?

Janku Filip has filed 5 SEC Form 4 filings (11 transaction rows) across 1 company since 2026.

Which companies does Janku Filip trade?

Janku Filip has filed SEC Form 4 disclosures for 1 company, including GLUE.

When was Janku Filip's most recent SEC Form 4 filing?

Janku Filip's most recent SEC Form 4 filing on Tracefour is dated Jul 1, 2026.

What is Janku Filip's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Janku Filip is listed as Chief Medical Officer.

What is Janku Filip's total buy and sell value in the current window?

Inside the rolling retention window, Janku Filip bought $0 and sold $1.4M based on SEC Form 4 filings.

What was Janku Filip's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 30,000 GLUE shares on 2026-06-24, worth $643K, per SEC Form 4 filings.